Literature DB >> 9317107

Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer.

L Fong1, C L Ruegg, D Brockstedt, E G Engleman, R Laus.   

Abstract

Prostatic acid phosphatase (PAP) is uniquely expressed in prostatic tissue and prostate cancer. In this study, the immunogenicity of PAP was investigated in a male rat model. We show that immunization with recombinant rat or human PAP in CFA leads to a significant Ab response, but does not generate CTL or result in autoimmune prostatitis. In contrast, immunization with recombinant vaccinia expressing human PAP, but not rat PAP, generates a CTL response and tissue-specific prostatitis in the absence of detectable PAP-specific Abs. These findings suggest that a cellular immune response to PAP, rather than Abs, mediates destructive autoimmune prostatitis. Thus, xenogeneic forms of PAP are a new tool for the induction of prostate-specific immunity and may prove useful for the immunotherapy of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9317107

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  An empiric victory.

Authors: 
Journal:  Nat Biotechnol       Date:  2010-06       Impact factor: 54.908

Review 2.  Update on prostate cancer vaccines.

Authors:  Charles G Drake
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 3.  Cytokine and endocrine signaling in prostate cancer.

Authors:  J Puente Vazquez; E Grande Pulido; L M Anton Aparicio
Journal:  Med Oncol       Date:  2011-08-20       Impact factor: 3.064

Review 4.  Immunotherapy for prostate cancer: biology and therapeutic approaches.

Authors:  Edward Cha; Lawrence Fong
Journal:  J Clin Oncol       Date:  2011-08-08       Impact factor: 44.544

Review 5.  New agents in the arsenal to fight castrate-resistant prostate cancer.

Authors:  Erin E Ezzell; Kuang S Chang; Benjamin J George
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

6.  Histopathological classification criteria of rat model of chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Xianjin Wang; Shan Zhong; Tianyuan Xu; Leilei Xia; Xiaohua Zhang; Zhaowei Zhu; Minguang Zhang; Zhoujun Shen
Journal:  Int Urol Nephrol       Date:  2014-11-20       Impact factor: 2.370

Review 7.  Potentiating prostate cancer immunotherapy with oncolytic viruses.

Authors:  Patrick Lee; Shashi Gujar
Journal:  Nat Rev Urol       Date:  2018-02-13       Impact factor: 14.432

8.  An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans.

Authors:  Yafei Hou; Jason DeVoss; Vinh Dao; Serena Kwek; Jeffrey P Simko; Douglas G McNeel; Mark S Anderson; Lawrence Fong
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

Review 9.  Experimental autoimmune prostatitis: different antigens induction and antigen-specific therapy.

Authors:  Yuqian Liu; Junaid Wazir; Meng Tang; Rahat Ullah; Yueting Chen; Tingting Chen; Xiaohui Zhou
Journal:  Int Urol Nephrol       Date:  2020-11-16       Impact factor: 2.370

10.  Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin.

Authors:  Oh-Joon Kwon; Li Zhang; Michael M Ittmann; Li Xin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.